Healthcare investment firm Vivo Capital has announced the final closing of its life science fund, Vivo Opportunity Fund, at an oversubscribed US$635 million, bringing the firm’s total funds under management to over US$2.2 billion.
UNLOCK DATA
Subscribe & Access the Best Data and Intelligence on Chinese Venture Capital and Tech
Want to read this important story?
Access thousands of news articles and data posts over the past 9 years!
